| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | 5.4% | n/a |
| ROCE | 7.6% |
| Latest | F'cast | |
|---|---|---|
| P/E | 45.0 | n/a |
| PEG | 0.7 | n/a |
| Pr/Revenue | 1.0 | n/a |
| Pr/Book | 0.8 |
| Latest | F'cast | |
|---|---|---|
| Revenue | -11.0% | n/a |
| PBT | 34.8% | n/a |
| EPS | 60.6% | n/a |
| DPS | n/a | n/a |
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Mar-21 | 105.61 | 19.31 | 10.86p | 29.7 | 0.3 | +88% | 1.00p | 0.3% |
| 31-Mar-22 | 82.19 | 1.39 | (1.01)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Mar-23 | 85.31 | 5.10 | 1.49p | 64.8 | n/a | n/a | n/a | 0.0% |
| 31-Mar-24 | 89.42 | 2.97 | 1.55p | 55.2 | 13.8 | +4% | n/a | 0.0% |
| 31-Mar-25 | 79.60 | 4.01 | 2.49p | 21.5 | 0.4 | +61% | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| ECOVAXXIN® MS EU marketing authorisation granted | 22-Dec-2025 | 07:00 | RNS |
| ECOVAXXIN® MS EU marketing authorisation gr... | 22-Dec-2025 | 07:00 | RNS |
| Exercise of Share Options by Director | 18-Dec-2025 | 07:00 | RNS |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 112.00p |
| Change Today | -2.00p |
| % Change | -1.75 % |
| 52 Week High | 116.40 |
| 52 Week Low | 51.50 |
| Volume | 112,733 |
| Shares Issued | 67.76m |
| Market Cap | £75.89m |
| Beta | 0.08 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| Latest | Previous | |
|---|---|---|
| Final | Final | |
| Ex-Div | 23-Sep-21 | 26-Sep-19 |
| Paid | 22-Oct-21 | 16-Oct-19 |
| Amount | 1.00p | 7.04p |
| Time | Volume / Share Price |
| 15:23 | 25,000 @ 112.00p |
| 15:17 | 7,500 @ 112.28p |
| 15:14 | 180 @ 111.00p |
| 14:07 | 6,984 @ 114.49p |
| 13:54 | 1,000 @ 114.96p |
| CFO | Christopher Wilks |
| CEO | David Hallas |
You are here: research